글로벌 임상 종양학 차세대 시퀀싱 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

미국 암 협회에 따르면, 2019년 미국에서 170만 건의 추가 암 사례와 60만 건의 암 사망이 발생했습니다. 폐암, 전립선암, 방광암, 여성 유방암은 전 세계적으로 가장 흔한 네 가지 암으로, 모든 신규 암 사례의 43%를 차지합니다. 결과적으로, 암 발병률이 전 세계적으로 증가함에 따라 임상 종양학 차세대 시퀀싱에 대한 수요가 증가할 것으로 예측됩니다. 임상 종양학 차세대 시퀀싱 회사는 정확도를 높이고 샘플 간 변동성을 낮추기 위해 워크플로 자동화에 점점 더 투자하고 있습니다.

Data Bridge Market Research는 2021년에 5억 9,256만 달러였던 임상 종양학 차세대 시퀀싱 시장이 2029년까지 1,825.30만 달러로 급증할 것으로 분석하고, 2022년부터 2029년까지 예측 기간 동안 15.1%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

Market Definition

Next-generation sequencing is a DNA or RNA technique that permits several reactions to be carried out simultaneously. This is one of the most important applications of next-generation sequencing in oncology. In recent years, NGS has changed cancer genetics by providing researchers greater access to genomic and transcriptome data. Next-generation tumour and germline DNA sequencing is used in oncology screening for therapeutic application.

Clinical Oncology Next Generation Sequencing Market Dynamics

Drivers

• Increase in cancer cases

The clinical oncology next-generation sequencing market is projected to be significantly impacted by personalized medicine and oncology improvements. Rising cancer prevalence, high acceptance of sequencing-based diagnostics platforms among practicing oncologists, decrease in the cost of genetic sequencing, and increased government R&D funding are some of the reasons expected to boost market growth. On the other hand, high adoption of this technique over single-gene testing and higher adoption of clinical oncology next-generation sequencing technology and platforms in academia projects will fuel a slew of new opportunities, propelling the clinical oncology next generation sequencing market forward from 2022 to 2029.

• New technological Innovatives

According to the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), cancer was the top cause of death worldwide in 2020, with over 10 million fatalities. In addition, 19.3 million additional cases were reported globally. New creative technologies, such as next generation sequencing, are being used to address this worldwide burden and lower mortality rates. As a result, the clinical oncology next generation market is growing at a faster rate.

• Reduction in the cost of NGS platforms

The factor aiding the market's growth is the reduction in the cost of NGS platforms. Clinical oncology next-generation sequencing approaches provide a high percentage of reads as well as low cost per read. Leading players are introducing low-cost sequencing approaches. Similarly, the worldwide clinical oncology next generation sequencing market will expand over the forecast period as more people use next generation sequencing for liquid biopsy.

Opportunities

Rapidly increasing cancer cases have become a major issue all over the world. The sickness not only kills people but also has a negative influence on countries' economies. As a result, the government and a variety of other healthcare organisations are taking steps to combat cancer's global burden. Research institutes are receiving large sums of money in order to find viable treatments and drugs. New studies are being launched to comprehensively examine the human genome.

 Restraints/Challenges

High cost coupled with technology is a major restraint to the growth of the clinical oncology next generation sequencing market in the above mentioned forecast period.  High costs connected with the installation of sequencing platforms, poor outsourced service efficiency, and limited availability of sequencing platforms in specific regional markets are all expected to restraint the overall development of the clinical oncology next-generation sequencing market.

This clinical oncology next generation sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the clinical oncology next generation sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Clinical Oncology Next Generation Sequencing Market

The COVID-19 epidemic hugely influenced the world as a whole, causing economic collapse and death. It has resulted in a worldwide pandemic that is extremely transmissible. With the advancement of technology, next-generation sequencing is becoming increasingly important in a variety of fields. From manufacturing PPE kits to inventing test kits to detect the virus and vaccines to prevent transmission, a number of pharmaceutical businesses and agencies have contributed to reducing the infection's impact. To combat the virus, businesses have strengthened their R&D and production workforce due to the increasing benefit of determining and finding the genetic sequence of a virus, which helps scientists to comprehend the virus's entire mutation, the overall influence on the next generation sequencing industry and market is expected to be beneficial.

Recent Development

• In January 2022, Agendia, Inc., a global pioneer in breast cancer precision medicine, announced a multi-year collaboration with Illumina to co-develop in vitro diagnostic (IVD) assays for oncology testing.
• In October 2021, Roche introduced the AVENIO tumour tissue CGP kit to make tailored cancer research more accessible.

Global Clinical Oncology Next Generation Sequencing Market Scope

The clinical oncology next generation sequencing market is segmented on the basis of technology, workflow, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing and Resequencing Centrifuges

Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

Application

• Screening
• Sporadic Cancer
• Inherited Cancer
•  
• Companion Diagnostics
• Other Diagnostics

End-user

• Hospitals
• Clinics
• Laboratories

Clinical Oncology Next Generation Sequencing Market Regional Analysis/Insights

The clinical oncology next generation sequencing market is analysed and market size insights and trends are provided by country, technology, workflow, application and end-user as referenced above.

The countries covered in the clinical oncology next generation sequencing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the clinical oncology next generation sequencing market due to the initiatives the governments have taken up for these technologies in the countries of this region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increasing automation in this region's pre-sequencing protocols.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Clinical Oncology Next Generation Sequencing Market Share Analysis

임상 종양학 차세대 시퀀싱 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 임상 종양학 차세대 시퀀싱 시장과 관련된 회사의 초점에만 관련이 있습니다.

임상 종양학 차세대 시퀀싱 시장에서 활동하는 주요 업체는 다음과 같습니다.

• 일루미나 주식회사(미국)
• Thermo Fisher Scientific Inc. (미국)
• F. 호프만-라 로슈 유한회사(스위스)
• Agilent Technologies Inc. (미국)
• Myriad Genetics Inc. (미국)
• BGI(중국)
• 퍼킨 엘머 주식회사(미국)
• 파운데이션 메디신 주식회사(미국)
• 팩바이오(미국)
• Oxford Nanopore Technologies plc. (영국)
• 패러다임 다이어그노스틱스 주식회사(미국)
• 카리스 라이프 사이언스(일본)
• Partek, Incorporated (미국)
• Eurofins Scientific(룩셈부르크)
• Qiagen(독일)

SKU-55964